Herpes Zoster Vaccination Reduces Risk of Dementia

STEVEN LEHRER1 and PETER H. RHEINSTEIN2

1Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.; 2Severn Health Solutions, Severna Park, MD, U.S.A.

Abstract. Background/Aim: The relationship of herpes viruses and herpes zoster (HZ) with dementia and Alzheimer's disease is controversial. This study evaluated the relationship between HZ vaccination and cognitive impairment. Patients and Methods: We used data from The Behavioral Risk Factor Surveillance System (BRFSS) to evaluate the relationship between HZ vaccination and cognitive impairment. Results: Using BRFSS 2017 data, we assessed HZ vaccination status in 275 subjects whose social activities were hampered by disorientation or memory loss. 61.6% of vaccinated subjects (n=61) and 46.6% of unvaccinated subjects (n=82) never had social activities hampered by disorientation or memory loss. The result is significant (p=0.025, two-sided Fisher exact test). The results of multivariate linear regression analysis, considering social activities hampered by disorientation or memory loss as a dependent variable, and vaccination (yes or no), sex, and education level as independent variables, showed that the effect of vaccination--reducing risk of social activities hampered by disorientation or memory loss--was significant (p=0.03). Conclusion: Our finding that HZ vaccination reduces the risk of dementia is consistent with the link between viruses and AD. Herpes viruses-induced reactivation of embryologic pathways silenced at birth could be one of the pathologic processes in Alzheimer's disease.

The relationship of herpes zoster (HZ) with dementia and Alzheimer's disease (AD) is controversial. HZ has been linked to a slightly higher risk of dementia, whereas antiviral therapy was linked to a lower risk of dementia in HZ patients (2). Tsai et al. discovered an elevated risk of dementia in patients infected with herpes zoster ophthalmicus (3). Other research (4) has supported these findings. However, in a case-control study, Choi et al. found that HZ did not raise the incidence of dementia (5).

Because of the possible connection between HZ and dementia, in particular AD, there is hope that an HZ vaccine might reduce the risk of dementia. In support of this, a lower risk for dementia following adult tetanus, diphtheria, and pertussis vaccination has been documented (6). Other vaccinations [Bacille Calmette-Guérin (BCG), influenza, COVID] may also be associated with reduced AD risk (7-10).

In the current study, we used data from The Behavioral Risk Factor Surveillance System (BRFSS) to evaluate the relationship between HZ vaccination and cognitive impairment.

Patients and Methods

The Behavioral Risk Factor Surveillance System (BRFSS) is the most comprehensive US system of health-related telephone surveys, collecting data on U.S. citizens' health-related risk behaviors, chronic health issues, and use of preventive services across the country (11). Recognizing the importance of cognitive decline as a public health concern, the Centers for Disease Control (CDC) through the Alzheimer's Disease and Healthy Aging Program created and deployed a BRFSS module to track subjective cognitive decline and its associated burden in the population, in partnership with national experts. Among the most predictive BRFSS module cognitive questions is one regarding interference with social activities. Social withdrawal is a common early symptom of neuropsychiatric disorders, a major driver of prognosis, and a significant cost to society. As neurological problems worsen, social withdrawal is frequently observed (12).

BRFSS participants are asked how often social activities are hampered by disorientation or memory loss (variable code name CDSOCIAL). We used this information in the current analysis to identify persons whose disorientation or memory loss makes it difficult for them to participate in social activities.
The interviewer specifically asked the following: During the past 12 months, how often has confusion or memory loss interfered with your ability to work, volunteer, or engage in social activities outside the home? Would you say: 1 – Always; 2 – Usually; 3 – Sometimes; 4 – Rarely; 5 – Never.

The 2017 data, used in the current study, had information on HZ vaccination. Module M07.01 (variable code name SHINGLE2) asks specifically about HZ vaccination. The interviewer first informs the patient of the following: Shingles is an illness that results in a rash or blisters of the skin and is usually painful. There are two vaccines now available for shingles: Zostavax, which requires 1 shot and Shingrix which requires 2 shots.

The interviewer then asks: Have you ever had the shingles or zoster vaccine?

Responses and their numerical designations were the following: 1. Yes, 2. No, 7. Don’t know/Not sure, 9. Refused. In the current study we included only answers 1 and 2.

The shingles vaccine would be mainly Zostavax (Merck), which was licensed by the FDA on May 26, 2006. Zostavax contains a weakened varicella-zoster virus. Zostavax reduced the risk of shingles by 51% and the risk of post-herpetic neuralgia by 67% in a study of more than 38,000 adults aged 60 years or older. Protection from Zostavax wanes after 5 years (13). FDA licensed Shingrix (GSK), a recombinant shingles vaccine on October 20, 2017; therefore, most Shingrix-vaccinated subjects are not included in the 2017 BRFSS data presented here.

Statistical methods. Univariate analysis of BRFSS data was performed by crosstabulation and a contingency table. Because one cell in the table had a zero value, the two tailed Fisher exact test was used to calculate statistical significance. Multivariate analysis was performed with linear regression. SPSS v 25 (IBM, NY, USA) was used for all calculations.

Results

We studied 275 subjects in the 2017 BRFSS data. Of those, 33% were male and 67% were female. The mean age of the 99 subjects who received the HZ vaccine was 70±7 years, whereas the mean age of the 176 subjects who did not receive the vaccine was 65±10 years. The age difference is statistically significant (p<0.001).

Table I shows the HZ vaccination status of 275 subjects versus the social activities hampered by disorientation or memory loss. 61.6% of vaccinated subjects (n=61) never had social activities hampered by disorientation or memory loss, whereas 46.6% of unvaccinated subjects (n=82) never had social activities hampered by disorientation or memory loss. The result is significant (p=0.025, two-sided Fisher exact test).

Table II shows the results of multivariate linear regression considering social activities hampered by disorientation or memory – loss as a dependent variable and vaccination (1 yes or 2 no), sex (1 male, 2 female), and education level as independent variables. B: unstandardized regression coefficient. The effect of vaccination-reducing risk of social activities hampered by disorientation or memory loss was significant (p=0.03).

Discussion

Even though vaccinated subjects were on average 5 years older than unvaccinated subjects, more vaccinated subjects (61.6%) than unvaccinated subjects (46.6%) never had social activities hampered by disorientation or memory loss. One would expect the opposite, since dementia incidence increases with age. Therefore, HZ vaccination appears to protect against dementia. A weakness in our study is that people whose social activities are unhampered would be more likely to seek vaccination.

About half of all dementia cases are caused by AD (14), but the link between viruses, particularly herpes, and AD is controversial. There is some evidence that taking anti-herpes drugs for a short period of time reduces the risk of dementia. Infection without antiviral treatment increases the risk somewhat. However, the results do not appear to be consistent across European countries (15). The antibacterial β-amyloid
found in the brains of AD patients could protect against herpes simplex type 1 (16), and our finding that HZ vaccination reduces the risk of dementia is consistent with the link between viruses and AD, which might be mediated by inflammaging.

Inflammation is part of aging. Chronic, sterile, low-grade inflammation, known as inflammaging, develops as people age and is associated with age-related disorders such as AD (17), cerebrovascular disease (18), and diminishing adaptive immunity (19).

AD, Lewy body dementia (LBD), and Parkinson's disease (PD) are all part of a continuum that could explain a variety of age-related neurodegenerative symptoms. Inflammaging is an important part of this process, since it is the long-term effect of persistent physiological stimulation of the innate immune system.

Because it may elaborate inflammatory chemicals and communicate with various organs and systems, the gut microbiome plays a crucial role in inflammaging. The gut microbiota has been linked to Parkinson's disease, and bacteria-produced proteins that mimic misfolded proteins involved in neurodegenerative disease may induce their misfolding (20).

GBA, BIN1, APOE, SNCA, and TMEM175 are five genes that have a role in determining whether a person will develop Lewy body dementia (LBD); some of these genes are also linked to Alzheimer's disease (AD) and Parkinson's disease (PD). Thus, the pathophysiology and course of AD, LBD, and PD would be different, depending on an individual’s genome. Although AD and PD are molecularly and clinically distinct disorders, their causes appear to underlie LBD. All three conditions lie on a continuum in vulnerable persons (Figure 1).
Our finding that HZ vaccination reduces the risk of dementia corroborates the results of other studies linking herpes viruses with AD. Viruses and inflammation are associated with cytokines and growth factors in AD. Furthermore, in the preimplantation embryo, cytokines affect gene expression, metabolism, and cell stress. Around the time of birth, the genes that cause these changes are silenced. However, they could ruin the same neuronal structures they formed in utero if reactivated in the brain by inflammation and viruses decades later. Therefore, herpes virus reactivation of embryologic processes and pathways silenced at birth could be one of the pathologic processes in Alzheimer’s disease.

Conflicts of Interest
The Authors have no conflicts of interest to declare in relation to this study.

Authors’ Contributions
Dr. Lehrer and Dr. Rheinstein contributed equally to the conception, writing, and data analysis of this study.

Acknowledgements
This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.

Research reported in this paper was also supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD018522 and S10OD026880. The content is solely the responsibility of the Authors and does not necessarily represent the official views of the National Institutes of Health.

References
17 Franceschi C, Garagnani P, Parini P, Giuliani C and Santoro A: Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 14(10): 576-590, 2018. PMID: 30046148. DOI: 10.1038/s41574-018-0059-4

18 Li T, Huang Y, Cai W, Chen X, Men X, Lu T, Wu A and Lu Z: Age-related cerebral small vessel disease and inflammaging. Cell Death Dis 11(10): 932, 2020. PMID: 33127878. DOI: 10.1038/s41419-020-03137-x

19 Kasler H and Verdin E: How inflammaging diminishes adaptive immunity. Nature Aging 1(1): 24-25, 2021. DOI: 10.1038/s43587-020-00021-3

20 Willyard C: How gut microbes could drive brain disorders. Nature 590(7844): 22-25, 2021. PMID: 33536656. DOI: 10.1038/d41586-021-00260-3

21 Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, Walton RL, Ahmed S, Viiolet C, Ding J, Makarious MB, Diez-Fairen M, Portley MK, Shah Z, Abramzon Y, Hernandez DG, Blauwendraat C, Stone DJ, Eicher J, Parkkinen L, Ansorge O, Clark L, Honig LS, Marder K, Lemstra A, St George-Hyslop P, London E, Morgan K, Lashley T, Warner TF, Jaunmuktane Z, Galasko D, Santana I, Tienari PJ, Myllykangas L, Oinas M, Cairns NJ, Morris JC, Halliday GM, Van Deerlin VM, Trojanowski QJ, Grassano M, Calvo A, Mora G, Canosa A, Floris G, Bohannan RC, Brett F, Gan-Or Z, Geiger JT, Moore A, May P, Krüger R, Goldstein DS, Lopez G, Tayebi N, Sidransky E, American Genome Center., Norcliffe-Kaufmann L, Palma JA, Kaufmann H, Shakkottai VG, Perkins M, Newell KL, Gasser T, Schulte C, Landi F, Salvi E, Cusi D, Masliah E, Kim RC, Caraway CA, Monuki ES, Brunetti M, Dawson TM, Rosenthal LS, Albert MS, Pletnikova O, Troncoso JC, Flanagan ME, Mao Q, Bigio EH, Rodriguez-Rodriguez E, Infante J, Lage C, González-Aramburu I, Sanchez-Juan P, Ghetti B, Keith J, Black SE, Masellis M, Rogaeva E, Duyckaerts C, Brice A, Lesage S, Xiromerisiou G, Barrett MJ, Tilley BS, Gentleman S, Logroscino G, Serrano GE, Beach TG, McKeith IG, Thomas AJ, Ametry J, Morris CM, Palmer L, Love S, Troakes C, Al-Sarraj S, Hodges AK, Aarsland D, Klein G, Woltjer R, Pastor P, Bekris LM, Leverenz JB, Besser LM, Kuzma A, Renton AE, Goate A, Bennett DA, Scherzer CR, Morris HR, Ferrari R, Albani D, Pickering-Brown S, Faber K, Kukull WA, Morenas-Rodriguez E, Lleó A, Fortea J, Alcolea D, Clarimon J, Nalls MA, Ferrucci L, Resnick SM, Tanaka T, Foroud TM, Graff-Radford NR, Wszolek ZK, Ferman T, Boeve BF, Hardy JA, Topol EJ, Torkamani A, Singleton AB, Ryten M, Dickson DW, Chiò A, Ross OA, Gibbs JR, Dalgard CL, Traynor BJ and Scholz SW: Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet 53(3): 294-303, 2021. PMID: 33589841. DOI: 10.1038/s41588-021-00785-3

Received July 12, 2021
Revised September 6, 2021
Accepted September 10, 2021